KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. A new study suggests that KT tape may not be effective ...

KT appointed Park Yoon-young as its new CEO at a shareholders meeting Tuesday and announced a sweeping organizational restructuring and executive reshuffle aimed at strengthening its core telecom ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...

Korean mobile carrier KT unveiled its 6G network road map, positioning the next-generation network as a social infrastructure for stable and reliable operation of artificial intelligence (AI), not an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated ...

The MarketWatch News Department was not involved in the creation of this content. KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 ...

My 'Hold' rating for KT Corporation is unchanged, following my assessment of its telco and non-telco business operations. Q4 2025 operating profit missed consensus by 3%, with a 58% sequential decline ...